Clinical trials
Breast cancer clinical trials
Cancer that forms in the cells of the breast, the most common cancer in women. We’re tracking 2,411 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05974150Recruiting
Remote symptom monitoring for several blood and cancer types
This study checks how well remote (at-home) symptom check-ins work for people with certain cancers. It may help patients and clinicians spot problems earlier and improve day-to-day care during treatment and beyond.
New Haven, ConnecticutAges 18 years+ - NCT06176534RecruitingPhase 2
Comparing two treatments for advanced breast cancer with low hormone receptor
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
Zhengzhou, HenanAges 18 years+ - NCT06611306Recruiting
Targeted whole-brain radiation for breast cancer that spread to the brain
This trial tests a newer, more targeted way to give whole-brain radiation for breast cancer that has spread to the brain. It aims to see if this approach can be as effective while causing fewer side effects compared to the standard whole-brain radiation.
London, LondonAges 16–100 - NCT04800393Recruiting
Breast surgery anesthesia and its effects on immunity and survival
This study compares two ways of giving anesthesia during breast cancer surgery to see how they affect the immune system and outcomes after surgery. It may help identify which anesthesia approach is better for people like you having early-stage, operable breast cancer surgery.
MoscowAges 45–74 - NCT02839863Recruiting
Breast cancer care follow-up at UMC Utrecht with surveys
This study follows people with breast cancer who receive radiation at UMC Utrecht. It uses routinely collected medical data and questionnaires to better understand outcomes over the long term.
AlmeloAges 18 years+ - NCT06341621RecruitingPhase 3
Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
ShanghaiAges 18–80 - NCT05460975Recruiting
Study of dense breast tissue seen on ultrasound
This study looks at breast cancer risk by analyzing what is seen in dense breast tissue during a screening ultrasound. It may help improve how doctors evaluate risk in people with very dense breasts.
SeoulAges 40–69 - NCT07520760RecruitingPhase 2
Eribulin Plus Anlotinib for HER2-Negative Breast Cancer
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
GuangzhouAges 18 years+ - NCT06553235Recruiting
App-based sleep and memory help for breast cancer survivors
This study tests whether an app-based program can improve sleep and thinking problems (like concentration and memory) in people who finished breast cancer treatment 1-5 years ago. If you have trouble sleeping and/or notice changes in your memory or focus, this trial may be able to help.
Aarhus NAges 18 years+ - NCT07503704Recruiting
Studying breast cancer that spread to the brain
This study looks at genetic material from spinal fluid to better understand breast cancer that has spread to the brain or its lining. It may help doctors find new ways to treat this type of cancer.
DublinAges 18–99 - NCT07396454RecruitingPhase 2
Radiation plus anlotinib for HER2-negative breast cancer brain metastases
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
NanjingAges 18–70 - NCT07331363Recruiting
Robot ultrasound for breast cancer screening
This trial tests whether using a robot to perform breast ultrasound can help find cancer early. You would use a smartphone to guide the screening, and the study compares this method to standard screening.
Xiantao, HubeiAges 35–64 - NCT07263451Recruiting
Testing a new treatment for small, early breast cancers
This study tests if a new treatment called IRE (irreversible electroporation) can safely treat small, early-stage breast cancers. It's for people with a single, small tumor that has not been treated yet.
Hangzhou, ZhejiangAges 18 years+ - NCT07137871RecruitingPhase 1
Avasopasem for advanced HR+ breast cancer after CDK 4/6 inhibitor
This trial tests a drug called avasopasem for people with hormone receptor-positive, HER2-negative breast cancer that has spread and gotten worse despite treatment with a CDK 4/6 inhibitor (ribociclib or abemaciclib) and hormonal therapy. It aims to see if adding avasopasem can help control the cancer.
San Antonio, TexasAges 18 years+ - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT06255392RecruitingPhase 3
Fluzoparib with apatinib vs chemo for advanced breast cancer
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Guangzhou, GuangdongAges 18–70 - NCT06633276Recruiting
Fast gene test for breast cancer diagnosis in Tanzania
This trial tests a new, fast method to diagnose breast cancer using a gene sequencing technique called nanopore sequencing. It aims to give accurate results quickly from a tumor sample taken during a biopsy or surgery.
MoshiAges 18 years+ - NCT06374459RecruitingPhase 1/Phase 2
Zunsemetinib and capecitabine for breast cancer with bone spread
This trial tests a new drug called zunsemetinib combined with the chemotherapy capecitabine for people with hormone receptor-positive, HER2-negative breast cancer that has spread to the bones. The goal is to see if this combination can better control the cancer.
Westwood, KansasAges 18 years+ - NCT05360290Recruiting
Study checks cancer cells in breast tissue after surgery
This trial looks for circulating tumor cells—cancer cells that may travel in the blood—after standard breast cancer treatment, including chemotherapy before surgery and surgery itself. It may help doctors understand who might be at higher risk and tailor follow-up care.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06738654Recruiting
Robotic breast-conserving surgery through the armpit for early-stage breast cancer
This trial tests a new robotic technique for removing early-stage breast cancer through the armpit, leaving no scar on the chest. It may be an option for women who want to keep their breast shape and avoid visible scarring.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT06533332RecruitingPhase 1
Testing ERX-315 for advanced solid tumors
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Ryde, New South WalesAges 18 years+
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer?
- Yes. Clin2 currently lists 2,411 recruiting breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.